查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844066

脑肿瘤诊断和治疗市场（按治疗方法、影像技术、最终用户、肿瘤类型、肿瘤分级和患者年龄组划分）－全球预测，2025-2032年

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脑肿瘤诊断和治疗市场规模将达到 37.3 亿美元，复合年增长率为 9.65%。

关键市场统计数据
基准年 2024 17.8亿美元
预计年份：2025年 19.5亿美元
预测年份 2032 37.3亿美元
复合年增长率 (%) 9.65%

本书清晰而有力地介绍了影响脑肿瘤诊断和治疗创新发展的临床、科学和卫生系统因素。

脑肿瘤的诊断和治疗方法正处于临床紧迫性、科学创新和医疗体系转型三者快速交会的阶段。分子生物学和诊断影像技术的进步正在重新定义临床医生对肿瘤的分类方式，从而实现更精准的诊断分类，为个人化治疗策略提供基础。同时，不断发展的外科手术技术、辅助放射治疗方法以及日益增多的标靶治疗和免疫疗法正在重塑不同肿瘤类型和年龄层患者的治疗路径。

这一领域由神经外科医师、神经肿瘤科医师、放射科医师、病理学家、转化科学家等多学科协作所构成。基因组分析、先进的磁振造影定序和功能性影像等技术的融合，为风险适应性治疗和更明智的临床决策提供了支持。然而，仍有大量未满足的医疗需求，尤其是在侵袭性肿瘤和罕见的儿童变异型肿瘤方面，这些肿瘤的持久疗效有限，治疗选择也十分狭窄。

因此，相关人员方正优先考虑诊断和治疗的整合开发，重点关註生物标记主导的临床试验、微创监测和真实世界证据的生成。本报告介绍了当前临床实践的关键主题、技术创新的发展轨迹以及医疗保健系统的应用，为后续的详细分析奠定了基础，并为开发人员、医疗服务提供者和支付方组装了切实可行的建议。

对正在重新定义整体医疗保健领域脑肿瘤诊断和治疗方法发展的主要技术、临床和护理服务变革进行深入分析。

脑瘤的诊断和治疗方法领域正经历多项变革性变化，这些变化共同改变了医疗服务的提供方式和产品的研发方向。在诊断层面，高解析度影像和分子病理学技术使得超越说明分类的精确表型分析成为可能。同时，免疫肿瘤学和细胞治疗方法正从实验平台发展成为可行的临床治疗方案，引发了人们对安全性监测、生产规模和长期追踪等方面的新思考。

影像学领域的创新，包括扩散张量成像、功能性磁振造影和氨基酸正子断层扫描示踪剂，提高了病灶的定性分析和治疗计划的製定，从而实现了更保守的切除和更优化的放射治疗靶向。外科手术的进步，例如术中可视化和萤光引导切除，在保留功能的同时扩大了切除范围，从而改变了辅助性治疗的决策。在治疗方面，标靶药物与免疫调节疗法结合的联合治疗已成为临床研发的重点，这需要更精细的生物标记策略和伴随诊断技术。

此外，数位健康、机器学习和真实世界数据正逐渐成为早期检测、预后建模和上市后监测的工具。这种转变既带来了机会，也带来了挑战。开发者必须应对监管机构对新型疗法的期望，而医疗系统则必须调整基础设施以支援多学科工作流程和先进的诊断技术。从孤立的创新模式转向整合式医疗路径，将决定哪些技术进步能真正改善病患的治疗效果。

评估近期关税主导的贸易行动可能如何重塑美国脑肿瘤诊断和治疗药物的供应链、采购和应用动态

关税等政策干预措施会对支持脑肿瘤诊断和治疗的生态系统产生广泛而累积的影响。影响成像设备、分子检测试剂以及用于先进外科手术和细胞疗法生产的专用耗材的进口措施，会增加直接采购成本，并延长关键工具的前置作业时间。这些压力会波及医院的资本规划和临床试验的后勤保障，减缓新型诊断平台的普及，并限制先进治疗方法的推广速度。

製造商和医疗系统可能会透过加快供应链本地化和投资国内高价值投入品的生产能力来应对。虽然将生产迁回国内可以缓解未来贸易相关的衝击，但这需要大量的资本投入和策略伙伴关係关係来确保品质和合规性。对于规模较小的开发商和学术机构而言，不断上涨的进口成本可能会促使他们优先考虑资本密集度较低的技术和能够减少初始硬体需求的授权合约。

在研究领域，关税可能会改变依赖统一成像和分子平台的多中心临床试验的经济效益，使数据协调和可比性变得复杂。临床合作者可能需要重新协商服务协议或调整通讯协定以应对设备差异。最终，相关人员应将关税相关影响视为推动供应多元化、策略采购以及产业、临床网络和政策制定者之间更紧密合作的催化剂，以保障关键诊断和治疗创新成果的可及性。

深入的细分综合分析表明，治疗方式、影像技术创新、终端用户、肿瘤类型、分级和患者人口统计特征如何反映策略重点。

从细分观点出发，可以更清楚地了解诊断和治疗领域中科学进步和机会的交会点。化疗包括烷化剂、抗代谢药物和铂类化合物，这些药物仍然是许多治疗方案的核心。同时，标靶治疗则着重于分子脆弱性的药物，例如抗血管新生药物、mTOR抑制剂和蛋白酪氨酸激酶抑制剂。免疫疗法包括CAR-T细胞疗法、查核点抑制剂和疫苗平台，这些疗法推动了联合治疗策略的发展，并需要专门的生产和安全性监测。这些治疗方法与肿瘤生物学和患者因素相互作用，从而影响治疗顺序和试验设计。

在诊断影像领域，市场由CT（电脑断层扫描）、MRI（磁振造影）、分子诊断、PET（正子断层扫描）和超音波细分市场所构成。磁振造影可进一步细分为扩散张量造影、功能性磁振造影和波谱分析，这些技术能够增强结构和功能评估；而正子断层扫描则利用胺基酸示踪剂和FDG来改善代谢评估。终端使用者包括门诊手术中心、诊断实验室、医院和研究机构，它们在资本密集度、工作流程需求和技术实施决策方面各不相同。

肿瘤类型可分为听神经瘤、胶质瘤、脑膜瘤和脑下垂体瘤，这些肿瘤有不同的临床病程和调控路径。肿瘤分级分为高级别和低级别，这对于预后和治疗强度至关重要。患者年龄层——成人、老年和儿童——带来了不同的生物学考量、剂量需求和监管保护，尤其是在儿童群体中，长期神经认知结果至关重要。整合这些细分视角，可以揭示在分子标靶标靶生物学、未满足的临床需求和可行的给药途径的交汇点上，投资和临床重点应该放在哪里。

全面的区域分析显示了美洲、欧洲、中东和非洲以及亚太地区各自如何影响临床应用、监管策略和商业化路径。

地理动态是技术采纳、监管路径和商业策略的关键决定因素。在美洲，临床试验能力、创投和整合医疗网络，以及强大的生物技术转化生态系统和先进的医院基础设施，正在促进新型诊断和治疗方法的快速应用。美国尤其如此，它仍然是早期临床试验和商业性上市的重点，但区域报销和政策差异会影响产品上市的速度。

欧洲、中东和非洲地区（EMEA）拥有领先的神经肿瘤中心，部分地区甚至拥有国家级研究网络，但其医疗保健系统和法规环境却存在差异。欧洲的法规结构强调严格的证据和成本效益，而海湾地区和北非的一些市场则大力投资于三级医疗，对高价值治疗方案产生了选择性需求。这些差异要求制定量身定制的打入市场策略和针对特定区域的证据产生方案。

亚太地区都市区化进程迅速，国内製造业产能不断增长，人口结构变化推动了对神经肿瘤服务的需求。该地区对成本高度敏感且报销机制多样，因此需要弹性价格设定和合作模式。同时，由于患者数量庞大且营运效率高，一些亚洲国家正成为后期临床试验的关键地点。跨区域合作和技术转移对于确保全球医疗标准的一致性和创新规模发展至关重要。

提供可操作的企业资料，概述策略伙伴关係、平台整合和製造投资如何使脑肿瘤诊断和治疗开发公司脱颖而出。

该领域的企业活动以策略伙伴关係、平台拓展以及对生产製造和数位化能力的定向投资为特征。将诊断平台与其治疗产品线整合或实现伴随诊断关联的企业，将透过协调研发和商业化时间表来获得竞争优势。生物製药开发商与诊断和影像供应商之间的合作日益受到生物标记主导的患者招募和即时疗效评估需求的推动。

关键的企业策略包括组成联盟以降低早期临床开发的风险、将细胞和基因疗法的专业生产外包，以及投资于用于成像和长期疗效监测的云端基础平台。併购仍然是快速获取能力的一种手段，尤其对于那些寻求整合分子检测、成像和临床决策支援以提供统一产品的公司而言更是如此。规模较小的创新企业经常透过收购或签订共同开发契约来扩展其生产和监管方面的专业知识，而规模较大的企业则专注于平台整合和全球市场渗透。

在竞争激烈的市场环境中，建立与支付方关係和展现医疗经济价值的敏捷性与科学差异化同等重要。那些积极应对实际应用挑战、简化临床工作流程并为医疗服务提供者提供培训和支援的公司，更有可能实现持续的市场认可和商业性成功。

为产业领导者提供清晰、优先的建议，以加速脑肿瘤治疗的研发，降低商业性风险，并展现其临床和经济价值。

产业领导者应采取一系列切实可行的优先事项，将科学前景转化为临床影响和永续的经营模式。首先，应优先投资于整合诊断技术，将分子谱分析与先进影像技术结合，以实现精准的病患筛选和适应性临床试验招募。这种方法可以降低研发风险，并提高展现显着临床效益的可能性。其次，应实现供应链多元化，并探索区域製造伙伴关係，以减轻贸易和关税的影响，同时确保价值链的连续性。

第三，我们将有意推行联合策略，在研发早期阶段协调监管和安全路径，并建立标准化的生物标记策略，以简化核准和报销流程。第四，我们将儘早与支付方和卫生技术评估机构合作，明确支持基于价值的合约的证据要求和病例定义。第五，我们将投资于真实世界证据和数据基础设施，以收集长期结果、生活品质指标和卫生经济学终点，从而支持药物的推广应用和纳入处方实践。

最后，应加强与学术中心、病患权益组织以及外科和放射科网路的跨部门合作，以加速临床应用，改善临床试验招募，并确保创新能解决实际医疗服务中的限制。采取这些措施有助于机构缩短产品上市时间，强化价值论证，最终改善复杂治疗领域的患者预后。

严谨透明的调查方法，结合文献回顾、专家访谈、临床註册分析和检验步骤，确保了研究结果的可靠性。

本分析的调查方法整合了多种互补途径，以确保其稳健性、有效性和实用性。此方法是基于对同行评审的临床研究、指南和公开监管文件的结构化文献综述和综合分析，旨在掌握目前的标准治疗方案和新兴证据。此外，还辅以一手研究，包括对临床专家、影像专家、临床实验研究人员和供应链管理人员的访谈，以阐明研究结果的背景并验证其与实际操作的契合度。

资料三角测量法用于整合不同的输入资料并检验主题结论。透过查阅临床试验註册库和近期会议论文集，我们整理了正在进行的研发项目，并识别了新疗法和诊断方法的发展趋势。在适当情况下，我们会分析技术规格和产品标籤，以了解其功能、限制和整合要求。此外，研究调查方法还包括情境分析，以检验监管变化、报销政策变化和供应链中断等变数如何影响产品推广应用的趋势。

我们承认存在一些局限性，包括区域实践模式的差异以及早期临床证据的持续演变。为了克服这些局限性，我们以清晰的证据等级呈现观察，并辅以专家意见。所有关键环节均指南伦理标准和资料完整性规范，并整合了保密的专家意见，以在确保资讯可操作性的同时保护匿名性。

策略性结论强调，要实际改善脑肿瘤治疗，需要整合诊断、进行协作开发以及采用主导医学方法。

总之，脑肿瘤的诊断和治疗领域正处于一个关键的十字路口，技术进步、不断演进的临床范式和不断变化的政策环境既带来了机会，也带来了挑战。整合诊断和定向治疗是未来发展的核心，但其成功取决于临床专科、监管机构、支付者和产业界的协同努力。影像学、分子谱分析和肿瘤免疫学的创新正在重新定义疾病分类和治疗路径，而供应链的韧性和策略伙伴关係关係对于维持医疗服务的可及性和规模至关重要。

相关人员投资于诊断和治疗合作、积极管理商业性和监管风险并优先考虑真实世界证据产生的利益相关者，最有可能实现可持续的临床和经济效益。我们迫切需要超越孤立的突破，转向系统层面的整合，从而改善患者选择、优化治疗顺序并保障患者的生活品质。这需要严谨的执行、清晰的价值论证以及以患者为中心的理念，将科学目标与可实现的临床效益相结合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 推出基于人工智慧的放射组学平台，用于个人化神经胶母细胞瘤治疗计划
  • 基于血液的液态生物检体检测方法的出现，为非侵入性检测和监测肿瘤復发提供了可能。
  • 引入术中萤光导航手术技术以增强肿瘤边缘切除效果
  • 靶向胶质瘤特异性抗原并具有更高穿透性的CAR-T细胞疗法发展迅速。
  • 拓展分子影像剂的应用范围，以实现对肿瘤代谢和治疗反应的即时评估
  • 开发一种可植入式药物输送系统，用于在脑肿瘤中局部和持续释放化疗
  • 可携式高场核磁共振造影系统在社区医疗保健中用于神经肿瘤诊断的商业化

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脑肿瘤诊断与治疗市场（依治疗方法）

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 铂化合物
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
    • 疫苗疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗
    • 抗血管新生药物
    • MTOR抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章 影像技术在脑肿瘤诊断与治疗市场的应用

  • 电脑断层扫描
  • 磁振造影
    • 扩散张量造影
    • 功能性磁振造影
    • 光谱学
  • 分子诊断
  • 正子断层扫描
    • 胺基酸示踪剂
    • FDG
  • 超音波

第十章 依最终使用者分類的脑肿瘤诊断与治疗市场

  • 门诊手术中心
  • 诊断实验室
  • 医院
  • 研究所

第十一章 按肿瘤类型分類的脑肿瘤诊断与治疗市场

  • 听神经瘤
  • 胶质瘤
  • 脑膜瘤
  • 脑下垂体瘤

第十二章 依肿瘤分级分類的脑肿瘤诊断与治疗市场

  • 优质
  • 低级

第十三章 依患者年龄层分類的脑肿瘤诊断与治疗市场

  • 成人
  • 老年人
  • 孩子们

第十四章 各地区脑瘤诊断与治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 脑肿瘤诊断与治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国脑瘤诊断与治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Siemens Aktiengesellschaft
    • General Electric Company
    • Koninklijke Philips NV
    • F. Hoffmann-La Roche Ltd.
    • Novocure Limited
    • Novartis AG
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Medtronic plc
Product Code: MRR-CA17E905E619

The Brain Tumor Diagnosis & Therapeutics Market is projected to grow by USD 3.73 billion at a CAGR of 9.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.78 billion
Estimated Year [2025] USD 1.95 billion
Forecast Year [2032] USD 3.73 billion
CAGR (%) 9.65%

A clear and compelling introduction to the current clinical, scientific, and health system forces reshaping brain tumor diagnosis and therapeutic innovation

Brain tumor diagnosis and therapeutics occupy a rapidly changing intersection of clinical urgency, scientific innovation, and health system transformation. Advances in molecular biology and imaging have reframed how clinicians classify neoplasms, enabling more precise diagnostic categories that inform individualized therapeutic strategies. At the same time, evolving surgical techniques, adjunctive radiation modalities, and a growing suite of targeted and immune-based therapies are reshaping treatment pathways across tumor types and patient age cohorts.

This landscape is defined by multidimensional collaboration among neurosurgeons, neuro-oncologists, radiologists, pathologists, and translational scientists. Technology convergence-combining genomic profiling, advanced MRI sequences, and functional imaging-now supports risk-adapted care and more informed clinical decision-making. However, significant unmet needs remain, particularly for aggressive high-grade tumors and rare pediatric variants where durable responses are limited and therapeutic windows are narrow.

Consequently, stakeholders are prioritizing integrated diagnostics and therapeutic development, with emphasis on biomarker-driven trials, minimally invasive monitoring, and real-world evidence generation. This report introduces the critical themes that govern current clinical practice, innovation trajectories, and health system adoption, setting the stage for the deeper analyses that follow and framing the practical implications for developers, providers, and payers.

Detailed analysis of the major technological, clinical, and care-delivery shifts that are redefining brain tumor diagnostics and therapeutic development across the care continuum

The landscape of brain tumor diagnosis and therapeutics is undergoing several transformative shifts that collectively alter how care is delivered and how products are developed. At the diagnostic level, high-resolution imaging and molecular pathology are moving beyond descriptive classification to enable precision phenotyping; this transition supports adaptive trial designs and targeted therapeutic strategies. Concurrently, immuno-oncology and cell-based therapies are progressing from experimental platforms to viable clinical options, prompting new considerations for safety monitoring, manufacturing scale, and long-term follow-up.

Imaging innovations, including diffusion tensor imaging, functional MRI, and amino acid PET tracers, are improving lesion characterization and treatment planning, thereby enabling more conservative resections and optimized radiation targeting. Surgical advances such as intraoperative visualization and fluorescence-guided resection are enhancing extent-of-resection while preserving function, which in turn changes adjuvant therapy decision-making. On the therapeutic front, combination regimens that pair targeted agents with immune-modulatory approaches are increasingly central to clinical development, necessitating more sophisticated biomarker strategies and companion diagnostics.

Additionally, digital health, machine learning, and real-world data are gaining prominence as tools for earlier detection, prognostic modeling, and post-market surveillance. These shifts create both opportunities and complexities: developers must navigate regulatory expectations for novel modalities while health systems must adapt infrastructure to support multidisciplinary workflows and advanced diagnostics. Transitioning from siloed innovation to integrated care pathways will determine which advances translate into meaningful improvements in patient outcomes.

Assessment of how recent tariff-driven trade measures could reshape supply chains, procurement, and adoption dynamics for brain tumor diagnostics and therapeutics in the United States

Policy interventions such as tariffs can exert a broad and cumulative influence on the ecosystem that supports brain tumor diagnostics and therapeutics. Import measures affecting imaging equipment, reagents for molecular testing, and specialized consumables used in advanced surgical and cell therapy manufacturing can increase direct procurement costs and extend lead times for critical tools. These pressures ripple through hospital capital planning and clinical trial logistics, potentially delaying adoption of newer diagnostic platforms and constraining the pace at which advanced therapeutic modalities are scaled.

Manufacturers and health systems may respond by accelerating localization of supply chains and investing in domestic manufacturing capacity for high-value inputs. While onshoring can mitigate future trade-related disruptions, it also requires significant capital investment and strategic partnerships to ensure quality and regulatory compliance. For smaller developers and academic centers, increased import costs may shift prioritization toward technologies with lower capital intensity or toward licensing agreements that reduce upfront hardware requirements.

In the research domain, tariffs can alter the economics of multicenter trials that rely on uniform imaging or molecular platforms, complicating harmonization and data comparability. Clinical collaborators may need to renegotiate service contracts or adapt protocols to account for equipment heterogeneity. Ultimately, stakeholders should view tariff-related impacts as a catalyst for supply diversification, strategic procurement, and closer collaboration between industry, clinical networks, and policy makers to safeguard access to critical diagnostic and therapeutic innovations.

Insightful segmentation synthesis explaining how therapeutic modalities, imaging innovations, end users, tumor typologies, grades, and patient age groups collectively inform strategic priorities

A segmentation-aware perspective clarifies where scientific advances and commercial opportunities are concentrated across diagnostic and therapeutic axes. Within therapeutic modality, chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy each contribute distinct mechanisms and clinical roles; chemotherapy includes alkylating agents, antimetabolites, and platinum compounds that remain core to many regimens, while targeted therapies emphasize antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors focused on molecular vulnerabilities. Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccine platforms that are driving combination strategies and necessitating specialized manufacturing and safety monitoring. These modalities interact with tumor biology and patient factors to shape treatment sequencing and trial design.

On the diagnostic imaging side, the market is organized across computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound. Magnetic resonance imaging further segments into diffusion tensor imaging, functional MRI, and spectroscopy that enhance structural and functional assessment, whereas positron emission tomography leverages amino acid tracers and FDG for improved metabolic evaluation. End users are defined across ambulatory surgical centers, diagnostic laboratories, hospitals, and research institutes, each exhibiting different capital intensity, workflow needs, and decision-making authority for technology adoption.

Tumor-type segmentation spans acoustic neuroma, glioma, meningioma, and pituitary tumor with divergent clinical courses and regulatory pathways, and tumor-grade classification into high grade and low grade remains pivotal for prognosis and treatment aggressiveness. Patient age cohorts-adult, geriatric, and pediatric-introduce distinct biological considerations, dosing imperatives, and regulatory protections, especially in pediatric populations where long-term neurocognitive outcomes are critical. Integrating these segmentation lenses reveals that investment and clinical emphasis are concentrated where molecularly targetable biology, unmet clinical need, and feasible delivery pathways converge.

Comprehensive regional analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape clinical adoption, regulatory strategy, and commercialization pathways

Geographic dynamics are a key determinant of technology adoption, regulatory pathways, and commercial strategy. In the Americas, clinical trial capacity, venture investment, and integrated care networks drive rapid uptake of novel diagnostics and therapeutics, complemented by a strong ecosystem for biotech translation and advanced hospital infrastructure. The United States in particular remains a focal point for early-phase studies and commercial launches, with regional reimbursement and policy changes influencing speed of access.

The Europe, Middle East & Africa region exhibits heterogeneous healthcare systems and regulatory environments, with pockets of excellence in advanced neuro-oncology centers and national research networks. European regulatory frameworks emphasize rigorous evidence and cost-effectiveness, while several Gulf and North African markets are investing in tertiary care capacity, creating selective demand for high-value interventions. These variations require tailored market access strategies and localized evidence generation.

Asia-Pacific is characterized by rapid adoption curves in urban centers, growing domestic manufacturing capabilities, and demographic trends that expand demand for neuro-oncology services. Cost sensitivity and diverse reimbursement landscapes in the region necessitate flexible pricing and partnership models, while several Asian countries are emerging as key sites for late-stage clinical trials due to patient volume and operational efficiencies. Cross-regional collaboration and technology transfer are increasingly important to ensure consistent standards of care and to scale innovations globally.

Actionable corporate intelligence outlining how strategic partnerships, platform integration, and manufacturing investments differentiate companies in brain tumor diagnostics and therapeutic development

Company behavior in this sector is characterized by strategic partnerships, platform extension, and targeted investments in manufacturing and digital capabilities. Firms that combine diagnostic platforms with therapeutic pipelines or that secure companion diagnostic linkages gain competitive advantage by aligning development and commercialization timelines. Collaboration between biopharma developers and diagnostics or imaging vendors is intensifying, driven by the need for biomarker-driven enrollment and real-time response assessment.

Key corporate strategies include forming consortiums to de-risk early clinical development, outsourcing specialized manufacturing for cell and gene therapies, and investing in cloud-based platforms for imaging analysis and longitudinal outcome monitoring. Mergers and acquisitions continue to be a lever for rapid capability acquisition, particularly for companies seeking to integrate molecular testing, imaging analytics, and clinical decision support into a coherent offering. Smaller innovators are frequently acquired or enter co-development agreements to scale manufacturing and regulatory expertise, while larger organizations focus on platform consolidation and global market access.

Across the competitive landscape, agility in forging payer relationships and demonstrating health economic value is becoming as important as scientific differentiation. Companies that proactively address real-world implementation challenges, simplify clinical workflows, and provide training and support to health systems are more likely to achieve durable adoption and sustained commercial performance.

Clear and prioritized recommendations for industry leaders to accelerate development, mitigate commercial risks, and demonstrate clinical and economic value in brain tumor care

Industry leaders should adopt a set of pragmatic, actionable priorities to convert scientific promise into clinical impact and sustainable business models. First, prioritize investment in integrated diagnostics that link molecular profiling with advanced imaging to enable precise patient selection and adaptive trial enrollment. This approach reduces development risk and enhances the likelihood of demonstrating meaningful clinical benefit. Second, diversify supply chains and consider regional manufacturing partnerships to mitigate trade and tariff exposure while ensuring continuity for high-value inputs.

Third, pursue combination strategies deliberately by aligning regulatory and safety pathways early in development and by establishing standardized biomarker strategies to streamline approval and reimbursement. Fourth, engage payers and health technology assessment bodies early to define evidence requirements and case definitions that support value-based contracting. Fifth, invest in real-world evidence and data infrastructure that captures longitudinal outcomes, quality-of-life metrics, and health economic endpoints to support uptake and formulary inclusion.

Finally, strengthen cross-sector collaborations with academic centers, patient advocacy organizations, and surgical and radiology networks to accelerate clinical adoption, improve trial recruitment, and ensure that innovations address practical care delivery constraints. These steps will help organizations reduce time to market, enhance value demonstration, and ultimately improve patient outcomes in a complex therapeutic area.

Rigorous and transparent research methodology combining literature synthesis, expert interviews, clinical registry analysis, and validation steps to ensure trustworthy insights

The research methodology underpinning this analysis integrates multiple complementary approaches to ensure robustness, validity, and practical relevance. The foundation comprises structured literature review and synthesis of peer-reviewed clinical studies, guidelines, and publicly available regulatory documents to capture the current standard of care and emergent evidence. This secondary research is augmented with targeted primary research, including interviews with clinical experts, imaging specialists, trial investigators, and supply chain managers to contextualize findings and confirm operational realities.

Data triangulation is used to reconcile differing inputs and to validate thematic conclusions. Clinical trial registries and recent conference proceedings are reviewed to map active development programs and to identify nascent therapeutic and diagnostic trends. Where appropriate, technical specifications and product labeling are analyzed to understand capabilities, limitations, and integration requirements. The methodology also includes scenario analysis to test how variables such as regulatory shifts, reimbursement changes, or supply-chain disruptions might affect adoption curves.

Limitations are acknowledged, including variability in regional practice patterns and the evolving nature of early-phase clinical evidence. To address these constraints, findings are presented with clarity about evidence level and are supplemented by expert judgment. Ethical standards and data integrity practices guide all primary engagements, and confidential input from experts is synthesized to preserve anonymity while preserving actionable insight.

Strategic conclusion emphasizing the need for integrated diagnostics, coordinated development, and evidence-driven adoption to realize meaningful improvements in brain tumor care

In conclusion, the field of brain tumor diagnosis and therapeutics stands at a pivotal juncture where converging technological advances, evolving clinical paradigms, and shifting policy environments create both opportunity and complexity. Integrated diagnostics and precision-directed therapeutics are central to future progress, but their successful translation will depend on coordinated efforts across clinical specialties, regulators, payers, and industry. Innovations in imaging, molecular profiling, and immuno-oncology are redefining disease classification and treatment pathways, while supply-chain resilience and strategic partnerships are essential to sustain access and scale.

Stakeholders that invest in linkage between diagnostics and therapeutics, proactively manage commercial and regulatory risk, and prioritize real-world evidence generation will be best positioned to realize durable clinical and economic outcomes. The imperative is to move beyond isolated breakthroughs toward systems-level integration that improves patient selection, optimizes therapeutic sequencing, and preserves quality of life. Doing so will require disciplined execution, clear demonstration of value, and a patient-centered focus that aligns scientific ambition with deliverable clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven radiomics platforms for personalized glioblastoma treatment planning
  • 5.2. Emergence of blood-based liquid biopsy assays for noninvasive detection and monitoring of tumor recurrence
  • 5.3. Implementation of intraoperative fluorescence-guided surgery techniques to enhance tumor margin resection
  • 5.4. Rapid growth of CAR T-cell therapies engineered to target glioma-specific antigens with improved penetration
  • 5.5. Expansion of molecular imaging agents enabling real-time assessment of tumor metabolism and therapeutic response
  • 5.6. Development of implantable drug delivery systems for localized and sustained release of chemotherapeutics in brain tumors
  • 5.7. Commercialization of portable high-field MRI devices for point-of-care neuro-oncology diagnostics in community settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutic Modality

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Platinum Compounds
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccine Therapy
  • 8.3. Radiation Therapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Antiangiogenic Agents
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Therapeutics Market, by Imaging Technology

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
    • 9.2.1. Diffusion Tensor Imaging
    • 9.2.2. Functional MRI
    • 9.2.3. Spectroscopy
  • 9.3. Molecular Diagnostics
  • 9.4. Positron Emission Tomography
    • 9.4.1. Amino Acid Tracers
    • 9.4.2. FDG
  • 9.5. Ultrasound

10. Brain Tumor Diagnosis & Therapeutics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type

  • 11.1. Acoustic Neuroma
  • 11.2. Glioma
  • 11.3. Meningioma
  • 11.4. Pituitary Tumor

12. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade

  • 12.1. High Grade
  • 12.2. Low Grade

13. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Brain Tumor Diagnosis & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Tumor Diagnosis & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Tumor Diagnosis & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Siemens Aktiengesellschaft
    • 17.3.2. General Electric Company
    • 17.3.3. Koninklijke Philips N.V.
    • 17.3.4. F. Hoffmann-La Roche Ltd.
    • 17.3.5. Novocure Limited
    • 17.3.6. Novartis AG
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Pfizer Inc.
    • 17.3.9. Johnson & Johnson
    • 17.3.10. Medtronic plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRAIN TUMOR